← All trials
NCT01244789
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2011
- Primary completion
- Jan 1, 2015
- Completion date
- Jan 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 678
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Danish Gynecological Cancer GroupLead sponsor
- European Organisation for Research and Treatment of CancerOverall official - principal investigator
- Danish Gynecological Cancer GroupStudy chair
- North Eastern Germany Society of Gynaecologic OncologyCollaborator
- Mayo ClinicCollaborator
- Nordic Society for Gynaecologic OncologyCollaborator
- European Organisation for Research and Treatment of CancerCollaborator
- Katholieke Universiteit LeuvenCollaborator
- Arbeitsgemeinschaft Gynaekologische Onkologie AustriaCollaborator
- Mario Negri InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.